

## Data Sharing Statement

Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2101544.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at <a href="https://www.janssen.com/clinical-trials/transparency">https://www.janssen.com/clinical-trials/transparency</a> . As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at <a href="http://yoda.yale.edu">http://yoda.yale.edu</a> .
When will data availability begin?	With publication
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	The study protocol and statistical analysis plan are available at NEJM.org.
When will supporting documents availability begin?	With publication
When will supporting documents availability end?	—
To whom will data be available?	N/A
For what type of analysis or purpose?	N/A
By what mechanism?	N/A
Any other restrictions?	N/A
Additional information	N/A

This statement was posted on April 21, 2021, at NEJM.org.